The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8592468 B1

PDF
Full Text
Expired
Date of Patent:
Nov. 26, 2013

Filed:

Mar. 23, 2011
Applicants:

Arne Holmgren, Stockholm, SE;

Jun LU, Stockholm, SE;

Alexios Vlamis-gardikas, Stockholm, SE;

Rong Zhao, Stockholm, SE;

Karuppasamy Kandasamy, Stockholm, SE;

Lars Engman, Uppsala, SE;

Lars Engstrand, Stockholm, SE;

Sven Hoffner, Stockholm, SE;

Inventors:

Arne Holmgren, Stockholm, SE;

Jun Lu, Stockholm, SE;

Alexios Vlamis-Gardikas, Stockholm, SE;

Rong Zhao, Stockholm, SE;

Karuppasamy Kandasamy, Stockholm, SE;

Lars Engman, Uppsala, SE;

Lars Engstrand, Stockholm, SE;

Sven Hoffner, Stockholm, SE;

Assignee:

Thioredoxin Systems AB, Sollentuna, SE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/425 (2006.01);
U.S. Cl.
CPC ...
Abstract

The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors ofTrxR with Kof 0.14 μM and 0.46 μM, respectively.mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains. Two major pathogenic bacteria, which previously had not been known to be sensitive to ebselen,(tuberculosis) and(stomach ulcer and cancer), were shown to be excellent targets.was also sensitive to ebsulfur.


Find Patent Forward Citations

Quick Actions:

Holmgren, Arne. (2013). Bacterial thioredoxin reductase inhibitors and methods for use thereof (U.S. Patent No. 8592468). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/8592468

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…